Manufacturing

Help shape industry insights. Take our survey on the biopharma impacts of the FDA Commissioner’s National Priority Vouchers program.

A new Cue Biopharma–ImmunoScape partnership seeks to advance targeted TCR-T expansion for solid tumors, supporting broader access and improved clinical durability.

Biologics output improves via planning and automation as digitalization predicts batch outcomes, requiring strong data and worker expertise, KBI Biopharma’s Sigma Mostafa explains.

The second installment of the monthly BioPharma By the Numbers infographic series details the hiring and retention challenges faced by US biopharma.

Abzena’s antibody platform enables Orion to streamline biologics development, showcasing trends in scalable, risk-reduced manufacturing for the industry.

SK pharmteco expands US peptide production capacity, strengthening domestic API manufacturing and accelerating biopharma process development.

Webinar Date/Time: Tue, Nov 18, 2025 11:00 AM EST

Fluorescence spectroscopy with A-TEEM offers rapid, precise monitoring of cell culture media variability for improved biopharmaceutical quality control.

This quiz measures your comprehension of one of our recent feature articles.

This quiz measures your comprehension of one of our recent feature articles.

Webinar Date/Time: Tue, Nov 11, 2025 11:00 AM EST

Cellevate’s nanofiber technology enables higher viral vaccine titers in adherent cell cultures, advancing efficiency in large-scale biomanufacturing.

Each step of development and manufacturing is becoming more interconnected, and BioPharm's September/October issue highlights the strategies, tools, and innovations shaping the future of the field.

Webinar Date/Time: Wed, Nov 5, 2025 11:00 AM EST

This second part of a two-part article provides a clear understanding of microbiological load reduction during cleaning processes in the non-sterile pharmaceutical manufacturing.

Jon Ellis, CEO, shares his thoughts on Trenchant BioSystems’ new technology, its reception within the cell and gene therapy sector, and the future nature of industry partnerships.

Comparing our survey results with recent headlines uncovered biopharma’s digital transformation paradox: high potential vs. low adoption.

In a session at the Cell and Gene Meeting on the Mesa, Prime Medicine CEO Allan Reine discussed how prime editing offers versatile, safe gene correction, but that delivery to target cells remains a major hurdle.

A growing demand for liquid medicines is driven by patient groups' unique needs, improving compliance through flexible and palatable dosing options.

A panel at the Cell and Gene Meeting on the Mesa discussed how advanced therapy production demands modular platforms, automation, and data governance to drastically improve patient access and affordability.

Naobios and Olon France create custom HCP ELISA to advance vaccine trials and strengthen global biopharmaceutical manufacturing capacity.

On July 31, President Donald Trump said the federal government would “deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices” should companies fail to comply.

Webinar Date/Time: Wed, Oct 22, 2025 11:00 AM EDT

Novartis expands its immunology pipeline with the Tourmaline acquisition and tests direct-to-patient model to reshape drug manufacturing strategies.

The 100% tariff on imported drugs will pressure biopharma companies to build manufacturing sites in the US or face significant costs.